Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.

Huang, Dan

Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. [electronic resource] - Cancer research Feb 2010 - 1053-62 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1538-7445

10.1158/0008-5472.CAN-09-3722 doi


Angiogenesis Inhibitors--pharmacology
Animals
Blotting, Western
Carcinoma, Renal Cell--blood supply
Cell Line
Cell Line, Tumor
Cell Movement--drug effects
Cell Proliferation--drug effects
Dose-Response Relationship, Drug
Endothelial Cells--cytology
Endothelium, Vascular--drug effects
Female
Humans
Indoles--pharmacology
Kidney Neoplasms--blood supply
Mice
Mice, Inbred BALB C
Mice, Nude
Neovascularization, Pathologic--genetics
Pyrroles--pharmacology
RNA Interference
Receptor, Platelet-Derived Growth Factor beta--genetics
Sunitinib
Tumor Burden--drug effects
Vascular Endothelial Growth Factor Receptor-2--genetics
Xenograft Model Antitumor Assays